targeted therapies in newly diagnosed aml: bcl2, flt3 and idh inhibitors
Published 1 year ago • 119 plays • Length 1:03Download video MP4
Download video MP3
Similar videos
-
2:08
comparing midostaurin to next-generation flt3 inhibitors in the frontline treatment of flt3-itd aml
-
0:57
potential approval of quizartinib in aml & its place in the aml treatment regimen
-
3:49
updates on anti-amyloid monoclonal antibodies for ad in phase iii trials
-
3:12
epad amyloid (english)
-
0:58
mcp 60 seconds with dr nadine abdallah on al amyloidosis
-
1:26
braf-mutated aml is associated with poor prognosis and myelodysplasia-related mutations
-
4:04
a hit-finding platform for the discovery of novel inhibitors of deubiquitinating enzymes (dubs)
-
5:24
safety by treatment phase and age when treating flt3-itd-mutated aml with quizartinib and chemo
-
6:11
disc diffusion assays
-
![[multidisciplinary] m3(r2)](https://i.ytimg.com/vi/O3JJjeh13SU/mqdefault.jpg)
1:01:31
[multidisciplinary] m3(r2)
-
3:11
afias 매뉴얼
-
4:44
azacitidine quizartinib for patients with mds and mpns with flt3 or cbl mutation
-
3:46
amr project biol-3471 fa24
-
1:54
fusion-aml-001: molecular changes associated with azacitidine & durvalumab in tp53m aml and hr-mds
-
2:00
flt3-itd-specific mrd predicts outcomes of chemotherapy in aml
-
2:40
an overview of the safety profile of flt3 inhibitors in aml
-
1:49
the prognostic value of flt3-itd residual disease in aml
-
2:33
everything about afias-3
-
3:23
flt3 and idh1/2 inhibitors
-
1:47
tp53 mutation-induced dysbiosis causes inflammation by impairing sialic acid metabolism
-
1:28
cd47 antibodies for the treatment of aml and mds: where is the field moving?
-
1:27
mrd detection for aml in china & mfc to detect cepba mutations